Patient characteristics, according to donor type
| . | . | Unrelated recipients . | |
|---|---|---|---|
| Characteristic . | Sibling recipients* (N = 1840) . | HLA 16/16–matched† (N = 194) . | HLA-DP GVH-mismatched‡ (N = 1023) . |
| Patient age, median years (range) | 44 (0–74) | 46 (2–75) | 44 (0–78) |
| Chronic myeloid leukemia, N (%) | 423 (23) | 57 (29) | 250 (24) |
| Female donor for male recipient, N (%) | 502 (27) | 45 (23) | 208 (20) |
| Mobilized blood cell graft, N (%) | 909 (49) | 88 (45) | 530 (52) |
| At least 900 cGy total body irradiation, N (%) | 691 (38) | 95 (49) | 477 (47) |
| Myeloablative conditioning, N (%) | 1552 (84) | 158 (81) | 787 (77) |
| . | . | Unrelated recipients . | |
|---|---|---|---|
| Characteristic . | Sibling recipients* (N = 1840) . | HLA 16/16–matched† (N = 194) . | HLA-DP GVH-mismatched‡ (N = 1023) . |
| Patient age, median years (range) | 44 (0–74) | 46 (2–75) | 44 (0–78) |
| Chronic myeloid leukemia, N (%) | 423 (23) | 57 (29) | 250 (24) |
| Female donor for male recipient, N (%) | 502 (27) | 45 (23) | 208 (20) |
| Mobilized blood cell graft, N (%) | 909 (49) | 88 (45) | 530 (52) |
| At least 900 cGy total body irradiation, N (%) | 691 (38) | 95 (49) | 477 (47) |
| Myeloablative conditioning, N (%) | 1552 (84) | 158 (81) | 787 (77) |